Mylan buys general derm drugs from Valeant
Canonsburg, Pa. — Mylan has purchased a span of general dermatology products from Canadian drugmaker Valeant Pharmaceuticals International, a Associated Press reports.
Mylan officials contend a association has acquired a rights to general versions of Valeant’s BenzaClin (clindamycin 1 percent/benzoyl peroxide 5 percent), a accepted acne treatment, and Efudex (fluorouracil 5 percent), a diagnosis for actinic keratosis. Terms of a understanding were not disclosed.
Mylan already creates a general chronicle of BenzaClin by a chartering agreement, and a understanding gives it a right to also make and sell an certified general chronicle of Efudex.
Valeant was compulsory to sell a drugs as partial of a 2011 understanding to buy Dermik, a dermatology multiplication of French curative organisation Sanofi.
Go back to a Dermatology Times eNews newsletter.